Mclean Hospital

In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression

July 14, 2020

HCP Live

Dr. Eric L. Ross and collaborators examine the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression.

Read Full Article
 
Journalist or member of the media?Media Contact

Topics

Depression Ketamine

You May Also Like

Predictors and Mechanisms of Symptom Change in Depression Treatment for Adolescents

How Ecstasy and Psilocybin Are Shaking Up Psychiatry

Electroconvulsive Therapy Effective for Depressed Patients With, Without Comorbid BPD

Alcohol Use on the Rise as Pandemic Continues Into Holiday Season

More

Resources

In the Media
Media Contact
News
Experts

Latest Videos

Woman talking to a clinician

The Truth About Trauma

Illustration of diverse friends with arms around each other on blue background

Coping With the Uncontrollable

Image of a woman holding up a picture of face with other pictures of emotions around her

Ask Me Anything About Emotional Regulation and BPD

Woman with headphones on looking at her laptop while on the couch.

Love Your Life Through the Science of Happiness

More
Videos

Back to top